Literature DB >> 31582968

The Diagnostic and Prognostic Values of C-Reactive Protein and Procalcitonin during Bacterial Infections in Decompensated Cirrhosis.

Sana Khedher1,2, Nasreddine Fouthaili1,2, Amira Maoui2,3, Sirine Lahiani2,3, Mohamed Salem1,2, Kahena Bouzid2,3,4.   

Abstract

BACKGROUND: Bacterial infection (BI) represents the main cause of decompensation and death in cirrhotic patients. Procalcitonin (PCT) and C-reactive protein (CRP) are two widely used biomarkers that may be helpful for early detection of BI especially in the presence of inflammation. Their accuracy for the diagnosis of BI in patients with chronic liver disease has been a subject of debate. In this study, we aimed to learn whether PCT and CRP would be helpful as early markers of BI in patients with cirrhosis and to evaluate their prognostic value in terms of mortality. SUBJECTS AND METHODS: We retrospectively included 92 adult patients with decompensated cirrhosis. PCT and CRP plasma levels were obtained within the first 24 hours of admission. Their diagnostic and prognostic values were compared using the appropriate statistical analysis.
RESULTS: Ninety-two patients were included. BI was diagnosed in 60 patients (65%). Mean white blood cell (WBC) count (p = 0.005) and PCT and CRP serum levels (p < 0.001) were higher in the BI group than in the non-BI (NBI) group. The diagnostic accuracy of CRP and PCT for the diagnosis of BI was better than that of WBC. CRP was the most sensitive marker (70%) while PCT was the more specific (96.6%). No one of those biomarkers was predictive of 3-month mortality in patients with BI.
CONCLUSION: Regarding BI in patients with decompensated cirrhosis, CRP maintains efficiency slightly higher than that of the PCT without being discriminative. However, no prognostic value has been established for these markers.
Copyright © 2018 Sana Khedher et al.

Entities:  

Year:  2018        PMID: 31582968      PMCID: PMC6748174          DOI: 10.1155/2018/5915947

Source DB:  PubMed          Journal:  Gastroenterol Res Pract        ISSN: 1687-6121            Impact factor:   2.260


1. Introduction

Cirrhosis is the advanced stage of a liver condition due to a chronic inflammatory and fibrosing prolonged evolving process. Cirrhotic patients are more susceptible to bacterial infection (BI) because of humeral and cell-mediated immunodeficiency, splanchnic ganglia colonization, bacterial translocation phenomena, and ventilatory disorders related to encephalopathy and ascites [1, 2]. BI is diagnosed in 30 to 50% of admitted cirrhotic versus 5 to 7% in noncirrhotic patients [3]. The diagnosis of BI in patients with cirrhosis is made difficult by some clinical and biological abnormalities commonly observed in those patients such as liver dysfunction, inflammation, chronic hypersplenism, abdominal distension, and neurological disorders in addition to the frequent use of betablockers. Despite the great improvement of BI management in cirrhotics, the mortality is still high. An early diagnosis and treatment of this condition, using biomarkers such as procalcitonin (PCT) and C-reactive protein (CRP), can contribute to reduce this mortality. This work is aimed at evaluating and comparing diagnosis and prognosis performance of CRP and PCT during BI in patients admitted for decompensated cirrhosis.

2. Methods

This 14-month observational retrospective study was conducted in the Hepato-gastroenterology Department of the Charles Nicolle University Hospital of Tunis from 01 September 2015 to 30 October 2016. We included patients admitted for decompensate cirrhosis. Cirrhosis was diagnosed according to histological and/or clinical, biological, and ultrasound findings suggesting portal hypertension and hepatocellular insufficiency. Decompensated cirrhosis was defined by the presence of ascites, jaundice, variceal hemorrhage, or hepatic encephalopathy. Patients not included in the study were those who were receiving intravenous antibiotics and those who were suffering from a systemic disease or a cancer including hepatocellular carcinoma. CRP and PCT are part of the routine biological sample performed at admission; we did not have to get patients' consent. The following severity and prognostic scores were used in our study: APACHE II score [4], Child-Turcotte-Pugh (CP) criteria [5], Model for End-Stage Liver Disease score (MELD) [6], CLIF-sequential organ failure assessment score (CLIF-SOFA), and Acute-on-chronic liver failure (ACLF) [7]. Blood samples for biological marker analysis as well as microbiological samples were obtained on admission. Serum CRP levels were measured using direct immunoturbidimetry on the Architect C 8000 Chemistry System (Abbott Diagnostics, USA). Enzyme-linked fluorescent immunoassay (ELFA) on mini-VIDAS (bioMérieux, France) was used for PCT tests. The patients were divided into a BI group and a non-BI (NBI) group. Dichotomous variables were expressed as percentages and continuous variables as mean ± standard deviation. Statistical comparisons were performed using, respectively, Student's t-test and χ2. Analysis of receiver operating characteristic (ROC) curves was used to determine diagnostic accuracy, sensitivity, and specificity and the Youden index to determine suggested cutoff. All analyses were conducted by SPSS 20.0 (SPSS Inc., Chicago, IL, USA). A p value of <0.05 was considered significant. Three-month mortality risk factors were determined by the application of multivariate logistic regression analysis. The authors state the absence of conflict of interest.

3. Results

Ninety-two patients were included with a sex ratio of 0.96 and a mean age of 63 ± 13 years (19-91). Mean follow-up time was 4.5 ± 4 years (3 months-26 years). Fifty-seven patients (61%) were CP class B and 32% class C. Hepatitis C was the most common etiology of cirrhosis (42%). They were mainly admitted for edemato-ascitic decompensation and the main source of infection was pulmonary tract infection (62%) and spontaneous bacterial peritonitis (23%). Baseline characteristics, cirrhosis etiologies, causes for admission, infection sources, and severity scores are summarized in Table 1. Distributions of sex, age, and comorbidities were similar between the two groups (Table 2). BI group had significantly higher encephalopathy rate (p = 0.005), higher body temperature (p = 0.008), higher heart rate (p = 0.025), higher total serum bilirubin level (p = 0.021), higher international normalized ratio (p = 0.005), lower prothrombin time (p = 0.005), and higher MELD score (p < 0.01). Mean serum levels of CRP (p < 0.001), PCT (p < 0.001), and white blood cells (WBC) (p = 0.002) were significantly higher in the BI group than in the NBI group (Table 2). The results of the logistic regression analysis showed that only MELD score > 15, encephalopathy, and PCT ≥ 0.5were significantly correlated to BI (Table 3). We evaluated the effectiveness of WBC, PCT, and CRP measurements in predicting infection in decompensated cirrhosis using the assessment of ROC curves. The area under the curve (AUC), sensitivity, specificity, positive and negative predictive values, and suggested cutoff values for each marker are summarized in Table 4. ROC analysis of CRP serum level showed the slightly higher AUC (0.745). PCT was more specific (96.6% vs. 75%) whereas CRP was more sensitive (70 vs. 45%).
Table 1

Baseline characteristics of patients.

Number of patients 92
Mean age, years 63 ± 13 (19-91)
Male,n 45
Female,n 47
Cirrhosis etiology,n(%)
Hepatitis C39 (42)
Hepatitis B9 (10)
Autoimmune hepatitis7 (8)
Primary biliary cirrhosis8 (9)
Alcohol3 (4)
Nonalcoholic steatohepatitis7 (8)
Cryptogenic13 (14)
Others4 (5)
Causes for admission,n(%)
Edemato-ascitic decompensation46 (50)
Hepatic encephalopathy23 (25)
Gastro-intestinal bleeding14 (15)
Fever14 (15)
Others9 (10)
Infection source,n(%)
Pulmonary tract infection37 (62)
Urinary tract infection12 (20)
Spontaneous bacterial peritonitis14 (23)
Skin infection5 (8)
Multiple sites6 (10)
Bacteremia9 (14)
Isolated3 (5)
Associated to another source6 (10)
Severity scores
Child-Pugh class (%)
A7
B61
C32
Child-Pugh, mean 10 ± 2 (6–15)
ACLF (%)
Grade 133
Grade 232
Grade 335
MELD score, mean 18 ± 7 (8-35)
APACHE II score, mean 20 ± 5 (12-34)

MELD: Model for End-Stage Liver Disease; APACHE II: Acute Physiology and Chronic Health Disease Classification System II; ACLF: Acute-on-chronic liver failure.

Table 2

Clinical and laboratory variables associated with infection on admission.

Bacterial infection groupn = 60Nonbacterial infection groupn = 32 p value
Age (yr)60 ± 1264 ± 150.509
Male/female30/3015/170.775
Medical history
 Diabetes mellitus38%44%0.614
 Hypertension28%41%0.231
 Tabagism28%19%0.350
 Alcoholism15%13%0.786
Child-Pugh (class)
 A1%6%0.123
 B28%44%0.256
 C70%50%0.456
 MELD score20 ± 715 ± 5<.001
 APACHE II score13 ± 815 ± 60.855
 CLIF-SOFA score15 ± 616 ± 60.757
ACLF
 Grade 132%38%0.573
 Grade 233%28%0.609
 Grade 334%34%0.952
Duration of stay (d)12 ± 812 ± 60.766
3-month mortality34%3%0.008
Vital signs
 Body temperature (°C)38 ± 0.737 ± 0.50.008
 Heart rate (beats/min)97 ± 1585 ± 180.025
 Respiratory rate (breaths/min)21 ± 420 ± 50.189
 Systolic blood pressure (mm Hg)108 ± 21111 ± 200.393
 Diastolic blood pressure (mm Hg)62 ± 1366 ± 100.193
 Encephalopathy72%37%0.005
 Ascite85%84%0.647
 WBCs (cells/lL)8750 ± 50055672 ± 27340.002
 Neutrophil (cells/lL)6430 ± 44563668 ± 21510.001
 Platelet (cells/lL)105056 ± 8090191000 ± 420630.361
 Serum BUN (mmol/L)8.8 ± 5.27.4 ± 5.90.282
 Serum creatinine (μmol/L)116 ± 10190 ± 510.167
 AST (IU/L)78 ± 10656 ± 380.350
 ALT (IU/L)43 ± 5540 ± 550.803
 Total bilirubin (mg/L)102 ± 13743 ± 450.021
 PT (%)48 ± 1858 ± 160.007
 INR1.91 ± 0.641.55 ± 0.360.005
 Albumin (g/L)25 ± 526 ± 50.579
 Serum sodium132 ± 5134 ± 40.177
 CRP (mg/L)46 ± 44.519.61 ± 24.95<.001
 PCT (ng/mL)1.84 ± 4.070.20 ± 0.48<.001

ALT: alanine aminotransferase; AST: aspartate aminotransferase; CRP: C-reactive protein; PCT: procalcitonin; INR: international normalized ratio; WBC: white blood cell; PT: prothrombin time; MELD: Model for End-Stage Liver Disease; APACHE II: Acute Physiology and Chronic Health Disease Classification System II; BUR: blood urea nitrogen; CLIF-SOFA: chronic liver failure-sequential organ failure assessment; ACLF: Acute-on-chronic liver failure.

Table 3

Univariate and multivariate analysis of factors associated with bacterial infection.

Bacterial infection diagnosis
Univariate analysisMultivariate analysis
Age > 60 years0.6090.285
Gender0.7750.399
Tabagism0.350.376
Alcoholism0.7860.076
Diabetes mellitus0.6140.75
Hypertension0.2310.535
Duration of cirrhosis0.1700.473
Length of hospitalization0.2910.843
Child-Pugh score0.3110.199
MELD score > 150.0010.022
Ascite0.9370.744
Encephalopathy0.0010.021
WBC ≥ 6635 cells/lL0.0050.22
CRP ≥ 20 mg/L0.0000.184
PCT ≥ 0.5 ng/mL0.0000.009

WBC: white blood cells; CRP: C-reactive protein; PCT: procalcitonin; MELD: Model for End-Stage Liver Disease.

Table 4

The results of ROC curve analysis for bacterial infection diagnosis.

AUC (95% CI) p Suggested cutoffSensitivity (%)Specificity (%)PPV (%)NPV (%)
WBC 0.694 (IC 95%: 0.585-0.803) 0.002 6635 65 65.5 78 50
CRP 0.745 (IC 95%: 0.635-0.855) <.001 20 70 75 84 57
PCT 0.741 (IC 95%: 0.639-0.843) <.001 0.5 45 96.6 97.5 59

WBC: white blood cells. CRP: C-reactive protein; PCT: procalcitonin; PPV: positive predictive value; NPV: negative predictive value.

3.1. Three-Month Mortality

Three-month mortality rate was 27%. Patients in the BI group had higher 3-month mortality rate (34% vs. 3%, p = 0.008) than those in the NBI group. However, multivariate risk factor analysis indicated that BI was not an independent 3-month mortality risk factor (Table 5). PCT serum level was significantly associated with 3-month mortality (p < 0.001). ROC analysis of PCT serum level showed the AUC of 0.735 (CI 95%: 0.576-0.895). Suggested cutoff was 0.5 ng/mL; sensitivity, specificity, positive predictive value, and negative predictive value were, respectively, 66.7%, 77.6%, 59%, and 82% (Figure 1). In the BI group, deceased patients were more often Child-Pugh class C and had lower temperature on admission, higher Child-Pugh score, higher leukocyte, neutrophil, and platelet counts, lower prothrombin time, and higher serum CRP, PCT, and creatinine levels (Table 6). In multivariate logistic regression mode, CP class C, lower temperature on admission, higher CP score, and higher platelet count were retained as predictors' parameters for three-month mortality (Table 7).
Table 5

Univariate and multivariate analysis of factors associated with 3-month mortality in admitted patients with decompensated liver cirrhosis.

Univariate analysisMultivariate analysis
Child-Pugh (class)0.0060.007
Encephalopathy0.0130.005
Infection0.0010.485
Heart rate0.0050.092
Temperature0.0550.547
WBC0.0010.331
Neutrophil count<0.0010.155
Platelets<0.0010.490
PT %0.0290.321
INR0.0360.962
CRP0.0010.053
PCT0.018<0.001
Serum creatinine0.014<0.001
AST0.095<0.001
Child-Pugh (score)0.0090.006
MELD<0.0010.091

WBC: white blood cells; INR: international normalized ratio; CRP: C-reactive protein; PT: prothrombin time; PCT: procalcitonin; AST: aspartate aminotransferase; MELD: Model for End-Stage Liver Disease.

Figure 1

ROC curves for procalcitonin (PCT), C-reactive protein (CRP), and white blood cells (WBC) in predicting 3-month mortality.

Table 6

Clinical and laboratory variables associated with 3-month mortality in the BI group.

SurvivingDeceased p value
Sex16/219/140.184
Child-Pugh (class)
 A0%3%0.427
 B4%43%0.001
 C96%54%0.001
Child-Pugh score10 ± 211 ± 10.004
Respiratory rate21 ± 321 ± 40.720
Temperature38 ± 0.837 ± 0.60.004
WBC (cells/lL)7632 ± 365110549 ± 63140.027
Neutrophil count (cells/lL)5369 ± 30498137 ± 57710.018
Platelets (cells/lL)83659 ± 66387139478 ± 912800.008
PT (%)51 ± 1941 ± 130.031
CRP (mg/L)37 ± 2961 ± 600.041
PCT (ng/mL)1.21 ± 2 ± 882.84 ± 5.390.131
Creatinine (μmol/L)96 ± 63150 ± 1390.045
AST (IU/L)63 ± 4491 ± 1620.396
MELD18 ± 723 ± 60.005

PT: prothrombin time; WBC: white blood cells; CRP: C-reactive protein; PCT: procalcitonin; AST: aspartate aminotransferase; MELD: Model for End-Stage Liver Disease.

Table 7

Univariate and multivariate analysis of factors associated with 3-month mortality in the BI group.

VariableUnivariate analysisMultivariate analysis
Sex0.1840.900
Child-Pugh (class)
 B<0.0010.887
 C<0.001<0.001
Child-Pugh (score)0.0040.627
Respiratory rate0.7200.111
Temperature0.0040.01
WBC0.0270.131
Neutrophil count0.0180.075
Platelets0.0080.018
Prothrombin time0.0310.874
CRP0.0410.225
PCT0.1310.318
Serum creatinine0.0450.197
AST0.3960.300
MELD score0.0050.411

WBC: white blood cells; CRP: C-reactive protein; PCT: procalcitonin; AST: aspartate aminotransferase; MELD: Model for End-Stage Liver Disease.

4. Discussion

In our study, the high rate of BI among patients with decompensated cirrhosis can be explained by the advanced liver failure observed in these patients. Our results showed that PCT and CRP serum levels were significantly higher in the BI group, and thus, these markers were useful in the diagnosis of BI in decompensated cirrhosis. Although they are mainly produced by the liver, hepatic insufficiency does not affect their diagnostic accuracy [8]. That is explained by a maintained hepatic production [9-11] and/or an extrahepatic production [12-15] of those two biomarkers during cirrhosis. On the other side, WBC count is deeply influenced by hypersplenism even if their production may be maintained. That can explain the less BI diagnosis accuracy of WBC observed in our study. Several studies have shown the reliability of PCT and CRP for the diagnosis of infection during cirrhosis with important AUC. In a recent meta-analysis including 1144 patients with liver cirrhosis, AUC for PCT and CRP was, respectively, 0.92 (95% CI: 0.89-0.94) and 0.87 (95% Cl: 0.84-0.90) [16]. This is probably due to differences in demographic characteristics and cirrhosis severity observed in our population. The cutoffs used are also different from ours. In the present study, diagnostic accuracy of CRP and PCT was comparable but it is still relatively low. That is why we think that PCT and CRP cannot be used alone to either confirm or exclude BI diagnosis. We found that, for the diagnosis of BI, CRP was more sensitive (70% vs. 45%) while PCT was more specific (96.9% vs. 75%). Similar results were reported by Lin et al.: CRP sensitivity was higher (87% vs. 79%) while PCT was more specific (89% vs. 85%) [16]. In addition, the CRP had a more discriminative value in the Papp study [17]. In order to enhance the diagnostic performance of CRP and PCT, the use of an algorithm that integrates clinical data with PCT or CRP can be helpful. In addition, it may be interesting to study the usefulness of an algorithm combing CRP and PCT.

4.1. Mortality

We have reconfirmed the gravity of BI in cirrhotics as already attested [18]. Three-month mortality was twelve times higher in infected patients compared to noninfected patients (34% vs. 3%, p = 0.08). However, multivariate risk factor analysis indicated that BI was not an independent 3-month mortality risk factor. Lazzarotto et al. did not find any association between infection at admission and death before the seventh day of hospitalization [19]. In Khot et al. study, sepsis was not objectively an independent predictor of mortality [20]. In our study, only serum PCT level was significantly related to 3-month mortality. The relationship between PCT and CRP levels and mortality reported in previous studies was contradictory [19, 21–23]. However, in the BI group, PCT and CRP did not show any prognostic value. That can be explained by the high severity of cirrhosis in the NBI group. In fact, the CP score influenced death. Our study has limitations. It is a monocentric study with a relatively small number of patients. In addition, PCT measurement was performed on admission regardless of the presence or the absence of infection.

5. Conclusion

Regarding BI in patients with decompensated cirrhosis, CRP maintains efficiency slightly higher than that of the PCT without being discriminative. However, no prognostic value has been established for these markers. In order to improve the diagnosis and reliability of prognosis, it may be interesting to combine them with each other or with other biological and/or clinical parameters.
  23 in total

1.  Acute phase proteins in the diagnosis and prediction of cirrhosis associated bacterial infections.

Authors:  Maria Papp; Zsuzsanna Vitalis; Istvan Altorjay; Istvan Tornai; Miklos Udvardy; Jolan Harsfalvi; Andras Vida; Janos Kappelmayer; Peter L Lakatos; Peter Antal-Szalmas
Journal:  Liver Int       Date:  2011-12-06       Impact factor: 5.828

2.  Serum leptin levels in alcoholic liver cirrhosis: relationship with gender, nutritional status, liver function and energy metabolism.

Authors:  B Campillo; E Sherman; J P Richardet; P N Bories
Journal:  Eur J Clin Nutr       Date:  2001-11       Impact factor: 4.016

3.  Prognostic value of C-reactive protein in cirrhosis: external validation from the CANONIC cohort.

Authors:  Jean-Paul Cervoni; Àlex Amorós; Rafael Bañares; Jose Luis Montero; German Soriano; Delphine Weil; Richard Moreau; Marco Pavesi; Thierry Thévenot; Vincent Di Martino
Journal:  Eur J Gastroenterol Hepatol       Date:  2016-09       Impact factor: 2.566

4.  Adding C-reactive protein and procalcitonin to the model of end-stage liver disease score improves mortality prediction in patients with complications of cirrhosis.

Authors:  Sakkarin Chirapongsathorn; Worawan Bunraksa; Amnart Chaiprasert; Dollapas Punpanich; Ouppatham Supasyndh; Patrick S Kamath
Journal:  J Gastroenterol Hepatol       Date:  2018-03       Impact factor: 4.029

5.  APACHE II: a severity of disease classification system.

Authors:  W A Knaus; E A Draper; D P Wagner; J E Zimmerman
Journal:  Crit Care Med       Date:  1985-10       Impact factor: 7.598

Review 6.  Bacterial infections in liver cirrhosis.

Authors:  M Navasa; J Fernández; J Rodés
Journal:  Ital J Gastroenterol Hepatol       Date:  1999-10

Review 7.  A model to predict survival in patients with end-stage liver disease.

Authors:  P S Kamath; R H Wiesner; M Malinchoc; W Kremers; T M Therneau; C L Kosberg; G D'Amico; E R Dickson; W R Kim
Journal:  Hepatology       Date:  2001-02       Impact factor: 17.425

8.  Expression of C-reactive protein by alveolar macrophages.

Authors:  Q Dong; J R Wright
Journal:  J Immunol       Date:  1996-06-15       Impact factor: 5.422

9.  Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis.

Authors:  Richard Moreau; Rajiv Jalan; Pere Gines; Marco Pavesi; Paolo Angeli; Juan Cordoba; Francois Durand; Thierry Gustot; Faouzi Saliba; Marco Domenicali; Alexander Gerbes; Julia Wendon; Carlo Alessandria; Wim Laleman; Stefan Zeuzem; Jonel Trebicka; Mauro Bernardi; Vicente Arroyo
Journal:  Gastroenterology       Date:  2013-03-06       Impact factor: 22.682

10.  Acute phase proteins for the diagnosis of bacterial infection and prediction of mortality in acute complications of cirrhosis.

Authors:  César Lazzarotto; Marcelo Fernando Ronsoni; Leonardo Fayad; Christiane Lourenço Nogueira; Maria Luiza Bazzo; Janaína Luz Narciso-Schiavon; Leonardo de Lucca Schiavon; Esther Buzaglo Dantas-Corrêa
Journal:  Ann Hepatol       Date:  2013 Jul-Aug       Impact factor: 2.400

View more
  4 in total

Review 1.  Liver cirrhosis and immune dysfunction.

Authors:  Elda Hasa; Phillipp Hartmann; Bernd Schnabl
Journal:  Int Immunol       Date:  2022-09-06       Impact factor: 5.071

2.  Sarcopenia Severity Based on Computed Tomography Image Analysis in Patients with Cirrhosis.

Authors:  Maryam Ebadi; Rahima A Bhanji; Abha R Dunichand-Hoedl; Vera C Mazurak; Vickie E Baracos; Aldo J Montano-Loza
Journal:  Nutrients       Date:  2020-11-11       Impact factor: 5.717

3.  Clinical significance and prognostic value of C-reactive protein/albumin ratio in gastric cancer.

Authors:  Qian Yu; Ke-Zhi Li; Yan-Jun Fu; Yanping Tang; Xin-Qiang Liang; Zhi-Qing Liang; Ji-Hong Bai
Journal:  Ann Surg Treat Res       Date:  2021-06-01       Impact factor: 1.859

Review 4.  Host Diagnostic Biomarkers of Infection in the ICU: Where Are We and Where Are We Going?

Authors:  Aaron J Heffernan; Kerina J Denny
Journal:  Curr Infect Dis Rep       Date:  2021-02-12       Impact factor: 3.725

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.